Can a single gene therapy injection reverse fatty liver disease?
NCT ID NCT07732400
First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time
Summary
This trial tests an experimental gene therapy called VV-14303 for people with metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition linked to obesity and diabetes. The therapy uses a harmless virus to deliver a protein (FGF21) that may improve liver health. Researchers are evaluating safety and whether it can reduce liver fat and damage in adults aged 18 to 75.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- VV-14303, an experimental gene therapy that delivers the FGF21 protein via a harmless virus, given as an injection into the muscle
- What this could lead to
- If successful, this could lead to a one-time gene therapy treatment for MASH, a serious liver disease with no approved therapies.
- What could go wrong
- This is an early, first-in-human trial with a small number of participants, so safety and effectiveness are not yet known. Gene therapies carry risks including immune reactions and long-term unknowns.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Kriya Clinical Trial Site
Chandler, Arizona, 85224, United States
Contact Email: •••••@•••••
-
Kriya Clinical Trial Site
Lady Lake, Florida, 32159, United States
-
Kriya Clinical Trial Site
Auckland, New Zealand
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Weight-Loss surgery beat drugs for advanced liver damage?
- Navy beans take on fatty liver: a diet swap put to the test
- Could a tailored diet make a MASH drug work better?
- New injections aim to melt liver fat in MASH patients
- New shot aims to reverse liver scarring in MASH patients
- New drug aims to melt liver fat and stop scarring in MASH patients